How our genes will change cancer

Doctors, researchers and audience gather at breakfast to learn about genetics, data and how working together will help beat cancer.

The time is 8:15. Many have started to file in and shuffle to their seats while chatting and occasionally sipping their first morning coffee. As it starts to quiet down, the lights are dimmed, the audience wake up and the breakfast meeting begins.

An air of seriousness with a hint of respect changes the atmosphere, and the audience watches as the first guest speaker steps in and introduces the concept of genes and their relation to cancer.

– Cancer is brought on by errors in our genes. Most of the time, cancer is a result of the unlucky, says Borge, who is the director at the Norwegian Biotechnology Advisory Board.

This is the start of his talk on genes and cancer, where the audience is introduced to that which defines us most: DNA, the molecule of life.

To the moon and back
– 20,310 recipes in our genetic material. 2 meters of DNA in every cell. 10 Billion cells, of which 20 billion meters of DNA is found. If you do the math, astonishingly it amounts to 26,015 trips back and forth to the moon, Borg says, as he shows us a visual representation on the powerpoint slide. (See video in Norwegian.)

It’s this incredibly long strand of genetic material where things can go horribly wrong. If there’s a genetic error, or mutation in the DNA that happens to take place between the double helix and if there’s enough errors, cancer happens. This is the unfortunate fate for many of us.

– However, we may not have come a long way in finding the ultimate cure for cancer, but what we have accomplished is the ability and possibility of analysing, and ultimately predicting, cancer through genome sequencing, Borge says.

It was the best of times…
This message, as a central theme to the breakfast meeting taking place, shines a hopeful light in an otherwise frightful and serious subject. With genome sequencing, or list of our genes, scientists and doctors will have greater accuracy to predict genes that are potential carriers, and highly susceptible to, different cancers.

However, this requires a large amount of genome sequences: we need an army of genome data.

From terminal to chronic
To set further example, the next speaker to take the stage is oncologist Odd Terje Brustugun. He stresses the importance of personalized treatment for lung cancer patients, even those with metastatic cancers. These patients can be tested today to see if they are viable to receive new kinds of treatmemt, such as targeted therapy. This was the case for lung-cancer patient, and survivor for five years, Kari Grønås.

Kari Grønås was able to participate in a clinical study. She was treated with targeted therapy instead of the ordinary treatment for lung cancer patients at that time: chemotherapy.

– I feel I have gone from feeling like I have a terminal disease to a chronic one, she says from the podium.

Beating cancer: the story of us
This personalized approach is arguably what worked for Kari, setting the example and potential for the future. If we can analyse our own genes for potential cancer, then we are both able to prevent and provide personalized medicine catered to the individual. This is why genome sequencing is important for the future.

However, this cannot be done alone. To get a representable treatment for the individual, we need data. And data does not come reliably from one individual, but from the many.

– It is not your genes that are the key for tomorrows cancer research, it is ours. It is collaboration where large amounts of data and correlation will give us the knowledge that ensures the right path towards the future. A future with better cancer treatment for all, says Ole Johan Borge.

A Constant State of Liveliness

A driving force behind the collaboration between Ullern Upper Secondary School and Oslo Cancer Cluster is stepping down. This is her adventure.

After fifteen great and productive years at Ullern Upper Secondary School, Esther Eriksen steps down from her position as vice principle in the upcoming month. Esther, who has been responsible for many various tasks in her position, has been a part of Ullern’s transformative experience alongside Oslo Cancer Cluster’s emergence in 2009 and recounts her time at Ullern.

A flourish of innovation
Esther Eriksen describes the transformation and unification of Ullern Upper Secondary School and Oslo Cancer Cluster as being a progression from a strong belief in it’s potential to a flourish of innovation.

The collaboration has become a constant state of liveliness: from pupils attending classes, to research, to teamwork and a continuous process of growth.

Since 2009, the school and the cluster, with all its member companies and institutions, has unified to produce a collaborative arena for the pupils. This is an experience Eriksen describes nothing short of “wonderful, educational and groundbreaking”.

Diversity in teamwork
– The collaborative experience is incredible due to the pupils’ ability to take in experience in regards to teamwork. Not to mention they learn how knowledge from books can be translated to hands on work and ultimately get a feel for what life has in store for them, says Eriksen.

Esther Eriksen describes her own experience as being much of the same, and stresses the notion of working as a team.

– Diversity in teamwork is really important! We see this from well-received results and happy pupils, says Eriksen.

Future potential
In regards to the future of this collaboration, Vice Principle Eriksen expresses her desire to see the school continue down the path it has set out on. She wants to see the pupils continue to learn, gain opportunities and continue to work collaboratively.

– I wish the pupils would gain further awareness of the potential this unification brings, and hope to see increased interest in teamwork as an integrity.

The best of moments
Esther Eriksen also shares what she would consider the best moments of her time at Ullern, of which these were her favorite:

  1. When the new school first opened in the Oslo Cancer Cluster Innovation Park in 2015 – hard work finally turned to fruition
  2. Seeing how happy and motivated the pupils are when they do projects with scientists, businesses and hospitals in the cluster
  3. The emergence of vocational studies, such as electronics and health care studies, at Ullern Upper Secondary School

To conclude, Vice Principle Eriksen would like to leave the school and her colleagues this message: that she will continue to observe and follow the thriving development taking place at Ullern Upper Secondary School.

– This is only the beginning!

 

Roche with approval for new lung cancer medication

Oslo Cancer Cluster member Roche has received approval for a medication against a specific form for lung cancer by the Norwegian Medicines Agency.  

 

Clinical data from a phase III study of the lung cancer medicine, named Alecensa, also shows significant approved survival for lung cancer patients.

This is important news for younger lung cancer patients because they have few treatments options today, often develop resistance to current standard of care within one year, and experience metastasis to the brain.

The specific form of lung cancer this drug, called Alecensa is approved for, is called anaplastic lymfomkinase (ALK) -positive advanced non-small cell lung cancer (NSCLC). In Norway lung cancer affects about 3 035 people per year. Of these almost five percent are ALK-positive. This cancer occurs mainly in young people of 50 years and under, with a specific type of non-small cell lung cancer, called adenocarcinoma. They normally smoke little or are non-smokers.

-We are glad that we finally can offer the lung cancer medicine Alecensa as a new treatment for Norwegian patients who no longer respond to the current standard treatment. We continue our efforts to improve research in personalised medicine to meet current unmet medical needs, says Elizabeth Jeffords, CEO of Roche Norway.

 

Clinical trials in Norway
Norwegian lung cancer patients have contributed to this study. Lead investigator in Norway is oncologist Åslaug Helland at Oslo University Hospital, Radium Hospital. She is one of the top ranked experts on this kind of lung cancer disease in Norway.

– Alecensa seems to be a very effective medication and is targeted for patients with ALK-positive lung cancer. About 90 people are diagnosed with this disease each year in Norway. This study has shown that the patients have good effect of the drug, with a long term effect and few side effects, says Helland.

Helland is pleased that a lot of new medications for lung cancer patients have been developed recently. She says this is due to the discovery of the driver-mutations for the disease.

– Lung cancer is the cancer that take the most lives in Norway, and we are glad for study results showing that patients can live longer without the disease worsening. Alecensa has now demonstrated efficacy both as first line therapy and second line therapy after treatment with crizotinib, says Jeffords.

 

About Alecensa
Alecensa (alektinib) is an oral drug, developed by Chugai Kamakura Research Laboratories of patients with non-small cell lung cancer whose tumors are assessed as ALK-positive. ALK-conditional positive, non-small cell lung cancer is often found in younger patients who are non-smokers, or who have previously smoked little. It is almost exclusively found in patients with a specific type of non-small cell lung cancer, called adenocarcinoma.

Alecensa has conditional marketing authorisation for the treatment of advanced (metastatic), ALK-positive, non-small cell lung cancer, where the condition is exacerbated by treatment with crizotinib.

 

Vaccibody moves forward with HPV-study

Oslo Cancer Cluster member Vaccibody is moving forward with the first vaccination of a patient with the human papillomavirus, HPV-virus, in a phase IIa study using the company´s immunotherapy platform. 

The primary objectives of the phase IIa study are to assess T cell mediated immune responses in the peripheral blood and to evaluate early signs of efficacy.

-We have been encouraged to see the outcome of the phase I trial and are excited to initiate this phase IIa clinical study. This offers a chance to get information on how patients respond to the Vaccibody immunotherapy platform, says Principal investigator, Prof. Dr. med. Karl Ulrich Petry, Department of Obstetrics & Gynaecology Klinikum Wolfsburg.

Moreover, the treatment can potentially also cure the underlying HPV infection, Petry comments, and thereby prevent recurrence and may protect from other HPV induced cancers.

 

Will outlicence the vaccine after phase II

– We are pleased to announce the vaccination of the first patient. Surgery is currently the only available therapy to remove abnormal cervical lesions caused by HPV-virus, and thereby stop the progression to cervical cancer, says Martin Bonde, CEO Vaccibody.

Bonde says that the plan is to have enough patients recruited by the end of Q3 and hence the first read out of the data in Q1, 2018.

-As of now we see that we will need a phase IIb/III study involving more patients, maybe up to 150-200. As of now we plan to out licence this product if we see the right responses, says Bonde.

 

About Vaccibody AS

Vaccibody is a biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, prophylactic and therapeutic vaccines which target cancer and infectious diseases, for human and veterinary use. Vaccibody’s lead program is focused on VB10.16, a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. Vaccibody also has a strong focus on so-called cancer neoantigen vaccines and is in late preclinical development with this program.

www.vaccibody.com

 

About Cervical Intraepithelial Neoplasia (CIN) and Cervical Cancer

Per year approximately 530,000 women are diagnosed with cervical cancer worldwide and over 275,000 women die of the disease annually. Invasive cervical cancer is preceded by a long phase of pre-invasive disease called Cervical Intraepithelial Neoplasia (CIN). Globally the number of high grade lesions (CIN 2/3) the immediate precursors to malignancy, is estimated to be in the range of 10 million.

Virtually all cervical cancers are caused by high risk HPV types. Among the different high risk HPV types known, HPV16 has been reported to be the most common genotype in high grade cervical intraepithelial neoplasia. It can be detected in up to 60 % of all cervical cancers, especially in younger women and it has also been found to play an essential role in the development of several other cancer types (approximately 90% of anal cancers; 40% of penile, vaginal, and vulvar cancers; 25% of oral cavity cancers and 35% of oropharyngeal cancers).

Current standard therapy for CIN 2/3 varies between countries and regions and often involves surgical removal of the affected tissue. These invasive procedures are associated with bleeding, infection, cervical stenosis, scarring and most importantly pre-term deliveries in subsequent pregnancies. As a result, there is a significant need for an effective therapeutic vaccine to treat existing HPV infection and associated pre-malignancies and malignancies of the cervix and thereby prevent the development of cervical cancer caused by human papillomavirus.

 

 

 

Try our matchmaking platform

Why join the PERMIDES platform? It is where you can find your biopharma-IT match.

 

“Since the launch of PERMIDES in September 2016, we have collected a lot of input from small and medium sized enterprises (SMEs). Several of our members have contributed by sharing their needs and challenges of digitalisation”, says Gupta Udatha, Project Manager for PERMIDES.

PERMIDES kicked off the matchmaking platform on March 15, 2017. During the following two weeks, approximately one hundred SMEs across the globe registered in the platform to find potential partners  for joint biopharma-IT innovation projects in personalised medicine.

There is plenty of room for more companies to benefit from the platform.

Potential project team partners can find each other on the PERMIDES platform. It offers matchmaking of companies from the biopharmaceutical and IT sector, based both on their needs and expertise”, says Udatha.

To be eligible for funding, project teams need to consist of one biopharma SME as the main applicant and at least one IT SME as the service provider.


Funding opportunities

PERMIDES offers different types of vouchers to SMEs allowing them to tackle and solve challenges at specific levels of complexity. Advancing personalised medicine in the digital age requires solutions to issues currently driving the IT and software sector, e.g. Big Data, machine learning, IT security, data protection, and cross-enterprise collaboration.

Each SME can apply for multiple vouchers, but is restricted to the maximum value of each voucher type as detailed at our Open Call for Financial Support. The voucher funding scheme of PERMIDES is aimed at SMEs for developing novel personalised medicine products and solutions.

It is the ambition of PERMIDES to accelerate the digitalisation of biopharmaceutical SMEs in the field of personalised medicine. This is a way of increasing the competitiveness of the participating SMEs.

For more information, visit permides.eu


Do you have questions?
We will be happy to have a meeting with your company and guide you through the PERMIDES funding and collaboration opportunities. Simply contact us if you have questions.

Gupta Udatha
gupta.udatha@oslocancercluster.no
455 34 627

Jutta Heix
jh@oslocancercluster.no
941 63 089

Utplassering på patologen ga mersmak

Ullern videregående skole har et unikt tilbud til sine elever. Gjennom det skolefaglige samarbeidet med Oslo Cancer Cluster kan de delta på utplasseringer hos medlemmene. Spennende, var gjennomgangstonen da vi besøkte de åtte elevene fra Ullern som denne uken har vært hos avdeling for patologi ved Oslo universitetssykehus. Marie Wahlstrøm  kan godt tenke seg å bli patolog.

 

– Dette er et snitt av en frisk livmorhals, sier Else Skovholt og justerer på mikroskopet slik at cellene i prøven, rosa, hvit og sort i fargen, trer tydelig fra.

Skovholt er patolog og sitter nå omringet av åtte elever fra Ullern videregående skole. De ser alle ned i hvert sitt mikroskop som viser samme bilde som Skovholt har lagt på.

– Men se her. Dette er et snitt av en livmorhals med celleforandringer forårsaket av HPV-virus. Om dere ser her så ser dere normalt vev, og så skjer det en glidende overgang til flere celler som sitter tettere sammen med mange mørke kjerner. Dette kan utvikle seg til kreft og må skjæres bort for ikke å gjøre det, sier Skovholt.

Alle jentene som er på utplassering er vaksinert mot dette viruset, og følger nøye med på gjennomgangen av friskt og sykt vev og hvordan se forskjellene på de ulike cellene som er på snittet.

– Tidligere i dag fikk vi se en livmor. Pasienten som den var fjernet fra ligger fremdeles på Radiumhospitalet rett over veien her, sier Marie Wahlstrøm fra klasse 2STE.

 

Et håndarbeid som viser hvem som er frisk og hvem som er syk

Elevene følge fascinert med ettersom Skovhold skifter ut snitt fra ulike prøver. Neste ut er eggstokker og eggledere, sædlederne og bryst. Rutinert viser hun elevene forskjellene på friskt vev, de ulike celletypene som er byggesteinene i de ulike organene og kreftceller. Spørsmålene er mange og Skovholt svarer enkelt på legspråk slik at alle får med seg alt.

På spørsmål om patolog er et yrke elevene kan tenke seg, er Marie krystallklar.

– Definitivt ja. Dette er et håndarbeid der du jobber praktisk i stedet for å sitte på kontor, du er med på å avgjøre om noen er syk eller frisk, og du vet at pasientene er rett her borte, så det blir veldig nært og føles veldig viktig, sier Wahlstrøm.

Patolog Marius Lund-Iversen bidrar også med sin spesialkunnskap. Over to dager har de åtte elevene tuslet opp i sjette etasje i den blå blokka i Oslo Cancer Cluster Innovasjonspark for å få skreddersydd kunnskap om et yrke som sårt trenger rekruttering.

Elevene har fått lage snitt, tappe eget blod for å analysere det for hvite og røde blodlegemer. De har også sett på ulike organer og hvordan de blir oppbevart på formalin, for så å bli snittet opp slik at de kan studeres i mikroskop.

Utplasseringen hos patologen skjer hvert år. Det er ett av mange tilbud som elever ved Ullern får takket være det skolefaglige samarbeidet mellom Oslo Cancer Cluster og Ullern videregående skole.

 

BerGenBio enters collaboration with MSD

Oslo Cancer Cluster member BerGenBio enters collaboration with MSD focused on clinical evaluation of BGB324 in combination with KEYTRUDA® (pembrolizumab) in advanced lung and breast cancer.

BerGenBio ASA is a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications. The company recently announced that it has entered into a collaborative agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada) , through a subsidiary, focused on the clinical evaluation of BGB324 with KEYTRUDA® (pembrolizumab) in patients with advanced non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

BerGenBio’s lead candidate BGB324 is a first in class, highly selective, potent and orally available small molecule Axl kinase inhibitor in clinical development in a variety of cancer indications. The Axl tyrosine kinase is a key driver of cancer spread, immune evasion and drug resistance – the cause of the majority of cancer-related deaths. Increased understanding of the role of Axl in suppressing innate immunity supports the rationale for evaluating BGB324 in combination with KEYTRUDA.

Under the terms of the collaboration with MSD, BerGenBio will conduct two international Phase II studies to evaluate the potential clinical synergy of combining BGB324 with MSD’s anti-PD-1 therapy, KEYTRUDA. Details of the studies are as follows:

  • BGBC007 – A Phase II multi-centre study of BGB324 in combination with KEYTRUDA in patients with previously treated, locally advanced or unresectable TNBC.
  • BGBC008 – A Phase II multi-centre study of BGB324 in combination with KEYTRUDA in patients with previously treated unresectable adenocarcinoma of the lung.

Biomarker studies will be conducted in parallel to the above studies with the goal of developing companion diagnostics to identify patients who would be most suitable for treatment with the BGB324/KEYTRUDA combination.

The clinical trials will be sponsored by BerGenBio while MSD will provide the trial with KEYTRUDA. The rights to the study results will be shared. No further details are disclosed.

BerGenBio is investigating BGB324 in multiple cancer indications based on preclinical and early clinical findings. Phase II studies with BGB324 as a single agent in relapsed acute myeloid leukaemia (AML) and myeloid dysplastic syndrome (MDS); and in combination with erlotinib (TARCEVA®) in advanced EGFR-positive NSCLC are in progress.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are delighted to enter this collaboration with MSD, a leader in developing novel cancer therapies. This new agreement gives us the opportunity to evaluate the clinical potential of BGB324 in combination with KEYTRUDA in advanced lung and breast cancer; two of the areas of significant unmet medical need. We believe that BGB324 is a unique drug candidate that addresses a critical cancer mechanism responsible for promoting immune evasion. We believe the clinical utility of BGB324 in combination with immunotherapies has enormous potential. BerGenBio is excited to advance BGB324 in combination with KEYTRUDA into Phase II trials and we anticipate results in mid-2018.”

About BerGenBio ASA
BerGenBio (Bergen, Norway) is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the central role of Axl kinase in promoting cancer spread, immune evasion and drug resistance in multiple aggressive liquid and solid cancers.

BerGenBio’s lead product, BGB324, is a selective, potent and orally available small molecule Axl inhibitor in Phase II clinical development in three major cancer indications. It is the only selective Axl inhibitor in clinical development. BGB324 is being developed by BerGenBio as a single agent therapy in acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS) and in combination with TARCEVA® (erlotinib) in advanced non-small-cell lung cancer (NSCLC); and in combination with KEYTRUDA® (pembrolizumab) in advanced NSCLC and triple negative breast cancer (TNBC) in collaboration with MSD.

The Company is also developing a diversified pre-clinical pipeline of selective Axl inhibitors including BGB149, anti-Axl monoclonal antibody.

For further information, please visit: www.bergenbio.com

About NSCLC
It is estimated that more than 220,000 new cases of lung cancer will be diagnosed in the US in 2017 and it is the leading cause of cancer death. 65% of NSCLCs are of adenocarcinoma pathology. Although various treatments exist for NSCLC, they are often curtailed by acquired resistance to therapy and immune evasion. Novel treatments overcoming these mechanisms in NSCLC are urgently required.

About TNBC
Breast cancer is the most common cancer in women – it is estimated that more than 250,000 new cases will be diagnosed in the US in 2017. 20% of breast cancers lack receptors for three common hormones (estrogen, progesterone and HER2) and are thus called triple-negative breast cancers (TNBC). Treatment options for TNBC are limited to intense chemotherapy, but despite therapy recurrences are frequent and aggressive. Consequently, novel treatment strategies for TNBC are of high need.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC.

 

We are hiring an EU Advisor

EU Advisor

We are currently looking for an EU advisor with skills and experience in writing EU funding proposals. This is a fixed term contract with duration to the end of 2018. If successful, this can become a long-term contract after 2018. We are also open to discuss a part-time employment. The EU advisor will report directly to the General Manager of OCC.

Key tasks:

  • Increase awareness of the H2020 funding opportunities and benefits among the cluster members incl. start-ups, SMEs and academic investigators
  • Actively support the cluster members with identifying relevant and appropriate H2020 funding schemes and call topics in 1:1 consulting meetings
  • Assist companies in development of project proposals in H2020 funding instruments
  • Pro-actively use OCC`s strong international network to identify new partners and suitable consortia for cluster members
  • Co-ordinate with other (national or Nordic) funding schemes and innovation agencies for achieving larger synergies and ensuring maximum impact
  • Organization and preparation of events and workshops for stakeholder information, education etc. addressing the needs of the cluster members
  • Development of project proposals to attract funding for OCC and OCC Incubator activities

Key qualifications:

  • Relevant scientific education, oncology background advantageous
  • 3 to 5-year experience in EU project applications and potentially project management
  • Innovation management experience and understanding of the different stakeholders in EU projects (start-ups, SMEs, academic partners, global companies)
  • Strong analytic capabilities and understanding of biomedical R&D, innovation challenges and business models
  • Self-driven, result oriented and disciplined
  • Fluent in written and spoken English

The EU advisor will be part of the Oslo Cancer Cluster team. OCC can offer competitive benefits, a positive working environment and colleagues with a strong drive and passion in the field of expertise. If you have any questions regarding this position, please contact Kelly Scientific and recruitment advisor, Janne Stang, cellphone: + 47 400 37 302. Kelly Scientific is a recruitment agency working with industry related positions within the Life Science sector.

Three new members in Oslo Cancer Cluster

IRW Consulting, Eisai and Personalis, Inc. are all new members of the Oslo Cancer Cluster. Please read more about them below.

 

IRW Consulting AB

IRW is a Nordic Contract Research Organization (CRO) with more than 15 years of experience in conducting clinical trials, Non-Interventional Studies (NIS) and medical device studies. IRW has built an extensive network throughout all Nordic countries, as well as the rest of Europe and the US. Depending on the customer’s requirements, our staff is either outsourced or works with in-house projects. We cover all the stages of clinical development, from phase I to phase IV, including pediatric and non-interventional studies and all classes of medical device investigations.

With regional offices in Denmark, Finland, Norway and Sweden, IRW has experienced locally-based staff providing an optimum combination of local knowledge and expertise to assist you conduct your clinical trial as per country specific guidelines. Local presence not just ensures adherence to local requirements for submissions to the Ethic Committees and Regulatory Authorities but also the knowledge of local language facilitates the communication with all local parties involved in the project thereby avoiding possible misunderstandings and reducing approval process timelines.

Working with the full range of companies, from small start-ups to multi-national pharmaceutical corporations, we have learned how to tailor our services to the specific needs of our customers.  Our involvement in clinical trials covers both Europe and the US, always following the appropriate regulations wherever we work, either according to external party’s SOPs or our own.
Home page IRW Consulting AB

 

Personalis, Inc.
Personalis, Inc., was founded in February 2011 out of Stanford University with the mission to provide precision, high accuracy genomic sequencing and analysis to enable precision medicine in the areas of cancer, immuno-oncology, and inherited disease.

Personalis provides researchers and clinicians with highly accurate, comprehensive, and validated DNA and RNA sequencing and interpretation of human genomic data for cancer research, clinical trials, and diagnostics. Our ACE (Accuracy and Content Enhanced) technology goes beyond standard sequencing approaches, substantially increasing medically relevant coverage and accuracy.

Personalis builds on this enhanced sequencing foundation with innovative algorithms and proprietary databases for alignment, variant calling, annotation, and analysis. Through this comprehensive approach, we provide genomic data and interpretation of the highest accuracy. Our CLIA-licensed and CAP-accredited laboratory, in combination with our validated, high accuracy ACE NGS platforms enable seamless transition from discovery to commercialization for our partners.

Home page Personalis, Inc.

 

Eisai

Eisai is a global pharmaceutical company addressing unmet medical needs, and Eisai is committed to make contributions to better healthcare for patients and their families around the world through its business activities.

Eisai has identified neurology and oncology as important areas where there are many diseases for which treatments are still not well established. Concentrating our R&D resources in these areas, Eisai is striving to discover new highly effective treatments especially for neurology and oncology.

Eisai carries out drug discovery research, drug development research and clinical research throughout the world. Eisai pursues innovative new drug discovery by promoting the exchange of various knowledge and ideas from around the world.

Main activities within oncology are within breast cancer and liposarcoma, where Halaven (eribulin) a cytotstatic agent, has shown survival benefit in both tumour types. Halaven is a novel anticancer agent discovered and developed by Eisai, has been launched in Japan, the United States, Europe and Asia.

Lenvima (lenvatinib), a multi targeted tyrosine kinase inhibitor (TKI), discovered and developed by Eisai, received orphan drug status and approval for radio-iodine refractory Differentiated Thyroid Cancer. Kisplyx (lenvatinib) was recently approved by EMA and FDA for use in advanced renal cell carcinoma. We are also involved in research in several other tumours.

Eisai AB is the Nordic affiliate and the Nordic office is in Stockholm.

Home page Eisai AB

 

 

 

 

Kronikk i Aftenposten: De nordiske landene kan gjøre noe resten av verden drømmer om

De nordiske landene bør samarbeide mer for å utvikle bedre kreftbehandlinger. Sammen kan Norden bli et globalt forsknings- og testsenter for nye kreftbehandlinger og -medisiner. Det kan gi store gevinster for kreftpasienter i hele verden. Denne kronikken sto på trykk i Aftenposten torsdag 9. mars.

Ketil Widerberg, daglig leder i Oslo Cancer Cluster, skrev kronikken samme uke som The Economist, Forskningsrådet og Oslo Cancer Cluster arrangerte den nordiske konferansen War on Cancer Nordics i Oslo. De nordiske landene ønsker å lede an i kampen mot kreft. Nå er det på tide at infrastrukturer og lovverk legges til rette for det.


Norden kan vise vei i kampen mot kreft. For vi har noe de andre – selv ikke USA – har


Design, TV-serier og nå: kreft
Nordisk design er verdenskjent, og nordisk film har gjennom TV-serier som Broen etablert en ny sjanger i underholdningsindustrien. På 1990-tallet endret Nokia og Ericsson hvordan vi brukte mobiltelefonen. Slike fremskritt setter Norden på det internasjonale kartet og skaper arbeidsplasser. Nå er tiden inne for liknende fremskritt i kampen mot kreft. Vi har gode forutsetninger, men er vi vårt ansvar bevisst?

Vi har fremragende kreftforskning, for eksempel innen immunterapi for kreft, fotodynamisk teknologi og radioaktive legemidler (radiofarmaka). På disse områdene gjør både nordiske forskere og bioteknologifirmaer det godt internasjonalt. Hver for seg er de nordiske landene små, men samlet har de over 26 millioner innbyggere, og er et interessant marked for forskning, bioteknologi- og legemiddelselskaper.


Norden har unike fortrinn
Norden har flere forutsetninger for å lykkes. Først og fremst har alle nordiske borgere et unikt personnummer. Dette mangler faktisk i mange andre land, som USA. Personnummer har gjort det mulig for nordiske myndigheter å samle unike helsedata. I over 60 år har de nordiske landene samlet helse- og kreftdata i biobanker og registre og bygd verdensledende helsesystemer. Den nordiske befolkningen har dessuten et stort digitalt liv, og samfunnet har generell tillit til forskning.

De nordiske landene kan bruke disse felles fortrinnene til å gjøre noe resten av verden drømmer om: bruke offentlige helsedata for å se hvilken lovende medisin som virker på hver enkelt pasient. Slik kan legemiddelet godkjennes og tas i bruk før de tradisjonelle tidkrevende og kostbare delene av klinisk utprøving blir satt i gang. Tiden det tar fra et kreftlegemiddel blir patentert til det blir godkjent til bruk vil bli kortere, og pasienten vil kunne få behandlingen flere år tidligere. Samfunnet vil kunne spare millioner. Norden bør være seg sitt ansvar bevisst og gå i bresjen for raskere utvikling av ny kreftbehandling. Vi har ikke råd til å vente.


Ny viten gir bedre behandling
Kreft er en av vår tids store samfunnsutfordringer. Hvert år dør 8 millioner mennesker av kreft i verden og 14 millioner av oss får en kreftdiagnose. Det er mange, og antallet vil øke. Ifølge Verdens helseorganisasjon vil det øke med hele 70 prosent de neste 20 årene.

Heldigvis øker også forståelsen av hvor komplekse sykdommene som vi kaller kreft er. Vi vet at det finnes over 200 kreftsykdommer, og vi vet at kreft påvirkes blant annet av genetiske faktorer. I tillegg har vi nå forstått at immunsystemet spiller en viktige rolle i utviklingen av ulike kreftsykdommer og at vi kan påvirke immunsystemet til å spille på lag med kroppen mot kreften. Økt kunnskap om hva kreft egentlig er gir oss bedre forutsetninger for å vinne kampen mot kreft. Men med ny viten følger også en ny dynamikk for hvordan behandling skal utvikles, kategoriseres og tilbys pasienter.


Tid for politisk vilje
Digitalisering av kreftforskning gir rask fremgang i mange land. Store globale teknologifirmaer som Microsoft, IBM og Google satser nå på helse, og spesifikt kreft. Med kunstig intelligens kan kreftforskere simulere, teste hypoteser og samle og korrelere data som ikke var mulig for kun få år siden. Norden har unike helsedatabaser, og vi kan bygge opp kompetanse sammen med globale selskaper på samme måte som Norge bygde opp oljeindustrien på 1970-tallet. Da inviterte Norge inn store internasjonale selskaper som utviklet oljeindustrien under statlig styring. Dette krevde samarbeid og tilrettelegging fra det offentlige.

En satsing på et nordisk kreftsamarbeid krever også offentlig tilrettelegging. Myndighetene og offentlige instanser må åpne for at forskere kan få bruke helsedataene vi allerede har. I Norden har vi strukturen som gjør det mulig å nå raskere fram med ny forskning. Vi kan hjelpe pasienter ved å godkjenne og ta i bruk legemidler før de tradisjonelle tidkrevende og dyre siste kliniske studiene settes i gang. Både USA og EU har forsøkt, men med begrenset hell, blant annet fordi de mangler personnummer og har fragmenterte helsesystemer. Der har de politisk vilje, men mangler strukturene.


Et globalt testsenter
Nordiske helsevesen samler inn stadig mer data fra befolkningen. Nå kan slike helsedata brukes til å utvikle medisiner raskere. Det vil stille nye krav til rapportering, sikkerhet og formål med bruk av helsedata. Det vil kreve en åpen og innovativ holdning både fra offentlige og private aktører. Dette er ikke risikofritt, men gevinsten for samfunnet og for den enkelte pasient som overlever takket være raskere og bedre behandling, vil være betydelig.

Norden har en unik mulighet til å være et globalt testsenter for utvikling av nye legemidler som utnytter den offentlige digitale infrastrukturen. Google endret hvordan vi bruker internettet. Vi gikk fra AltaVista til Google, og så oss aldri tilbake. Norden har alle forutsetninger for å lede an i digitaliseringen innen helse. Det kan være med på å endre livet til de 14 millionene nye menneskene som får kreft hvert år.

Ketil Widerberg, daglig leder i Oslo Cancer Cluster